

Orf1/SpcS Chaperones ExoS for Type Three Secretion by *Pseudomonas aeruginosa*¹

DA-KANG SHEN^{*#2}, LAURIANE QUENEE^{*2}, MARIETTE BONNET^{*}, LAURIANE KUHN^{\$}, MADIHA DEROUAZI^{*}, DANIELE LAMOTTE^{*}, BERTRAND TOUSSAINT^{*}, AND BENOIT POLACK^{*3}

^{*}Groupe de Recherche et d'Etude du Processus Inflammatoire (GREPI), MENRT EA 2938, Centre Hospitalier Universitaire de Grenoble, BP 217, 38043 Grenoble Cedex 9, France; [#]Department of Microbiology and Parasitology, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China; ^{\$}Laboratoire de Chimie des Protéines, DRDC, CEA Grenoble, 38054 Grenoble, France

Objective *Pseudomonas aeruginosa* is a ubiquitous and opportunistic pathogen that uses the type III secretion system (TTSS) to inject effector proteins directly into the cytosol of target cells to subvert the host cell's functions. Specialized bacterial chaperones are required for effective secretion of some effectors. To identify the chaperone of ExoS, the representative effector secreted by the TTSS of *P. aeruginosa*, we analyzed the role of a postulated chaperone termed Orf1. **Methods** By allelic exchange, we constructed the mutant with the deletion of gene *Orf1*. Analysis of secreted and cell-associated fractions was performed by SDS-PAGE and Western blotting. Using strain expressing *in trans* *Orf1*, tagged by V5 polypeptide and histidine, protein-protein interaction was determined by affinity resin pull-down assay in combination with MALDI-TOF. The role of *Orf1* in the expression of *exoS* was evaluated by gene reporter analysis. **Results** Pull-down assay showed that *Orf1* binds to ExoS and ExoT. Secretion profile analysis showed that *Orf1* was necessary for the optimal secretion of ExoS and ExoT. However, *Orf1* had no effect on the expression of *exoS*. **Conclusion** *Orf1* is important for the secretion of ExoS probably by maintaining ExoS in a secretion-competent conformation. We propose to name *Orf1* as SpcS for "specific *Pseudomonas* chaperone for ExoS".

Key words: Type III secretion system; *Pseudomonas aeruginosa*; Chaperone

REFERENCES

1. Banwart B, Splaingard M L, Farrell P M, et al. (2002). Children with cystic fibrosis produce an immune response against exoenzyme S, a type III cytotoxin of *Pseudomonas aeruginosa*. *J Infect Dis* **185**, 269-270.
2. Moss J, Ehrmantraut M E, Banwart B D, et al. (2001). Sera from adult patients with cystic fibrosis contain antibodies to *Pseudomonas aeruginosa* type III apparatus. *Infect Immun* **69**, 1185-1188.
3. Roy-Burman A, Savel R H, Racine S, et al. (2001). Type III protein secretion is associated with death in lower respiratory and systemic *Pseudomonas aeruginosa* infections. *J Infect Dis* **183**, 1767-1774.
4. Hauser A R, Cobb E, Bodi M, et al. (2002). Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by *Pseudomonas aeruginosa*. *Crit Care Med* **30**, 521-528.
5. Galán J E, Collmer A (1999). Type III secretion machines: bacterial devices for protein delivery into host cells. *Science* **284**, 1322-1328.
6. Barbieri J T, Sun J (2004). *Pseudomonas aeruginosa* ExoS and ExoT. *Rev Physiol Biochem Pharmacol* **152**, 79-92.
7. Yahr T L, Vallis A J, Hancock M K, et al. (1998). ExoY, an adenylate cyclase secreted by the *Pseudomonas aeruginosa* type III system. *Proc Natl Acad Sci USA* **95**, 13899-13904.
8. Phillips R M, Six D A, Dennis E A, et al. (2003). *In vivo* phospholipase activity of the *Pseudomonas aeruginosa* cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors. *J Biol Chem* **278**, 41326-41332.
9. Aldridge P, Hughes K T (2001). How and when are substrates selected for type III secretion? *Trends Microbiol* **9**, 209-214.
10. Feldman M F, Cornelis G R (2003). The multitalented type III chaperones: all you can do with 15 kDa. *FEMS Microbiol Lett* **219**, 151-158.
11. Page A L, Parsot C (2002). Chaperones of the type III secretion pathway: jacks of all trades. *Mol Microbiol* **46**, 1-11.
12. Parsot C, Hamiaux C, Page A L (2003). The various and varying roles of specific chaperones in type III secretion systems. *Curr Opin Microbiol* **6**, 7-14.
13. Finck-Barbançon V, Yahr T L, Frank D W (1998). Identification

¹This research was supported by the association "Vaincre la Mucoviscidose" of France.

²Da-Kang SHEN and L Quénée contributed equally to this work.

³Correspondence should be addressed to Benoît POLACK. Tel: 33-4-76765487. Fax: 33-4-76765935. E-mail: BPolack@chu-grenoble.fr

Biographical note of the first author: Da-Kang SHEN, male, born in 1971, M. D., Ph. D., associated professor, Shanghai Jiaotong University School of Medicine, majoring in microbiology and parasitology.

0895-3988/2008
CN 11-2816/Q
Copyright © 2008 by China CDC

- and characterization of SpcU, a chaperone required for efficient secretion of the ExoU cytotoxin. *J Bacteriol* **180**, 6224-6231.
14. Yahr T L, Hovey A K, Kulich S M, *et al.* (1995). Transcriptional analysis of the *Pseudomonas aeruginosa* exoenzyme S structural gene. *J Bacteriol* **177**, 1169-1178.
 15. Frank D W (1997). The exoenzyme S regulon of *Pseudomonas aeruginosa*. *Mol Microbiol* **26**, 621-629.
 16. Toussaint B, Delic-Attree I, Vignais P M (1993). *Pseudomonas aeruginosa* contains an IHF-like protein that binds to the algD promoter. *Biochem Biophys Res Commun* **196**, 416-421.
 17. Dacheux D, Toussaint B, Richard M, *et al.* (2000). *Pseudomonas aeruginosa* cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils. *Infect Immun* **68**, 2916-2924.
 18. Quénée L, Lamotte D, Polack B (2005). Combined *sacB*-based negative selection and *cre-lox* antibiotic marker recycling for efficient gene deletion in *Pseudomonas aeruginosa*. *BioTechniques* **38**, 63-67.
 19. Shen D K, Filopon D, Kuhn L, *et al.* (2006). PsrA is a positive transcriptional regulator of the type III secretion system in *Pseudomonas aeruginosa*. *Infect Immun* **74**, 1121-1129.
 20. Persson C, Nordfelth R, Holmstrom A, *et al.* (1995). Cell-surface-bound *Yersinia* translocate the protein tyrosine phosphatase YopH by a polarized mechanism into the target cell. *Mol Microbiol* **18**, 135-150.
 21. Wattiau P, Bernier B, Deslee P, *et al.* (1994). Individual chaperones required for Yop secretion by *Yersinia*. *Proc Natl Acad Sci USA* **91**, 10493-10497.
 22. Abe A, de Grado M, Pfuetzner R A, *et al.* (1999). Enteropathogenic *Escherichia coli* translocated intimin receptor, Tir, requires a specific chaperone for stable secretion. *Mol Microbiol* **33**, 1162-1175.
 23. Frithz-Lindsten E, Rosqvist R, Johansson L, *et al.* (1995). The chaperone-like protein YerA of *Yersinia pseudotuberculosis* stabilizes YopE in the cytoplasm but is dispensable for targeting to the secretion loci. *Mol Microbiol* **16**, 635-647.
 24. Fu Y X, Galán J E (1998). Identification of a specific chaperone for SptP, a substrate of the centisome 63 type III secretion system of *Salmonella typhimurium*. *J Bacteriol* **180**, 3393-3399.
 25. Niebuhr K, Jouihri N, Allaoui A, *et al.* (2000). IpgD, a protein secreted by the type III secretion machinery of *Shigella flexneri*, is chaperoned by IpgE and implicated in entry focus formation. *Mol Microbiol* **38**, 8-19.
 26. Pederson K J, Krall R, Riese M J, *et al.* (2002). Intracellular localization modulates targeting of ExoS, a type III cytotoxin, to eukaryotic signalling proteins. *Mol Microbiol* **46**, 1381-1390.
 27. Zhang Y, Barbieri J T (2005). A leucine-rich motif targets *Pseudomonas aeruginosa* ExoS within mammalian cells. *Infect Immun* **73**, 7938-7945.
 28. Cheng L W, and Schneewind O (1999). *Yersinia enterocolitica* type III secretion - on the role of SycE in targeting YopE into HeLa cells. *J Biol Chem* **274**, 22102-22108.
 29. West S E H, Schweizer H P, Dall C, *et al.* (1994). Construction of improved *Escherichia-Pseudomonas* shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in *Pseudomonas aeruginosa*. *Gene* **128**, 81-86.

(Received March 12, 2007 Accepted December 3, 2007)